Evidence map›Paper›PMID 38911560›Full record

ArticleAnnals of translational medicine2024

FLT3 inhibitor maintenance after allogeneic stem cell transplantation in

Gong He, Erika Belmont, Theodore Karrison, Wendy Stock, James L LaBelle, Satyajit Kosuri, Richard A Larson, Justin P Kline, Peter A Riedell, Mariam Nawas and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gong HeSection of Hospital Medicine, University of Chicago, Chicago, IL, USA.
Erika BelmontInternal Medicine Residency Program, University of Chicago, Chicago, IL, USA.
Theodore KarrisonPublic Health Sciences, University of Chicago, Chicago, IL, USA.
Wendy StockDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
James L LaBelleDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Satyajit KosuriDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Richard A LarsonDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Justin P KlineDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Peter A RiedellDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Mariam NawasDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Michael R BishopDepartment of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Hongtao LiuDivision of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The somatic mutation of fms-like tyrosine kinase 3 ( Methods: We performed a single center, retrospective cohort study and analyzed patients who had Results: FLT3i maintenance therapy was started at a median 59 days (range, 29-216 days) after allo-HSCT with median duration of 287 days (range, 15-1,194 days). Maintenance therapy was well tolerated. Overall, the improvement in DFS rates for patients after they were placed on FLT3i maintenance therapy was not significant [hazard ratio (HR) for relapse or death =0.65, 95% confidence interval (CI): 0.32-1.31, P=0.23]. However, when adjusted for the conditioning regimen and donor status, the differences were statistically significant with improvement in DFS and OS for patients on FLT3i maintenance (HR for OS =0.42, 95% CI: 0.18-0.95, P=0.04). Conclusions: When adjusting for conditioning regimen and donor status, there was a significant improvement in DFS and OS for patients who received FLT3i maintenance therapy compared to those who did not. Randomized prospective studies may provide more insight.

Indexed as

acute myeloid leukemia (AML)FLT3 inhibitor (FLT3i)Fms-like tyrosine kinase 3 (FLT3)maintenancerelapse

Identifiers

PMID38911560
PMCPMC11193555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.